Seres Therapeutics, Inc. (MCRB) P/E Ratio History
Deep ValueTrading at 10.3x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2025–2025
Loading P/E history...
P/E Ratio Analysis
As of June 23, 2026, Seres Therapeutics, Inc. (MCRB) trades at a price-to-earnings ratio of 10.3x, with a stock price of $6.60 and trailing twelve-month earnings per share of $-4.89.
The current P/E is 62% below its 5-year average of 27.0x. Over the past five years, MCRB's P/E has ranged from a low of 22.5x to a high of 31.5x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, MCRB trades at a 53% discount to its sector peers. The sector includes 233 companies with P/E ratios ranging from 0.0x to 194.5x.
Relative to the broader market, MCRB trades at a notable discount to the S&P 500 median P/E of 24.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our MCRB DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
MCRB Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
MCRB P/E vs Peers
Microbiome and Phage Therapeutics peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 9.6Lowest | - | +68%Best | |
| $16B | 34.6 | 14.49Best | +42% | |
| $143B | 18.4 | - | -4% | |
| $557B | 39.9 | - | -58% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
MCRB Historical P/E Data (2025–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Dec 31 2025 | $14.88 | $0.66 | 22.5x | -17% |
| FY2025 Q3 | - | $19.24 | $0.61 | 31.5x | +17% |
Average P/E for displayed period: 27.0x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
1+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
MCRB — Frequently Asked Questions
Quick answers to the most common questions about buying MCRB stock.
What is MCRB's P/E ratio?
Seres Therapeutics, Inc. (MCRB) trailing twelve-month P/E ratio is 10.3x, based on TTM diluted EPS of $-4.89. The 5-year average P/E is 27.0x and the historical range spans 22.5x to 31.5x.
Is MCRB stock overvalued or undervalued?
MCRB trades at 10.3x P/E, below its 5-year average of 27.0x. At the 0th percentile of its historical range (22.5x–31.5x), the stock is priced at a discount to its own history.
Is MCRB stock expensive?
No, MCRB is not expensive on a historical basis. The current P/E of 10.3x is below the 5-year average of 27.0x and sits at the 0th percentile of its valuation range.
What is MCRB's historical P/E range?
Over the past 5 years, MCRB's P/E ratio has ranged from 22.5x to 31.5x, with a median of 31.5x and an average of 27.0x. The current P/E of 10.3x places the stock at the 0th percentile of this range. Full historical data spans 2025–2025.
How does MCRB's P/E compare to the S&P 500?
MCRB trades at 10.3x P/E versus the S&P 500 median of 24.3x. The 58% discount to the market suggests lower growth expectations or perceived higher risk.
How does MCRB's valuation compare to Healthcare peers?
Seres Therapeutics, Inc. P/E of 10.3x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is MCRB's PEG ratio?
MCRB PEG ratio is N/A, based on a P/E of 10.3x and EPS growth of 103.4%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is MCRB's earnings yield?
MCRB earnings yield is 9.70%, the inverse of its 10.3x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.